Roslin Cells inked a contract with the Neusentis research unit of Pfizer to support the manufacture of retinal pigment epithelium cells to be used in a cell therapy clinical trial. The trial will evaluate the therapy for the treatment of patients suffering from age-related macular degeneration, the major cause of loss of vision in people aged 65 and older, as part of an ongoing collaboration with The London Project at the Institute of Ophthalmology, UCL.

Manufacturing will take place in Roslin Cells’ GMP cellular therapy manufacturing facility in Edinburgh, which was licensed by the Medicines Healthcare Products Regulatory Agency in May 2013 for the manufacture of human cell therapy products for clinical trials.








This site uses Akismet to reduce spam. Learn how your comment data is processed.